[go: up one dir, main page]

Vahl et al., 2003 - Google Patents

Effects of GLP-1-(7–36) NH2, GLP-1-(7–37), and GLP-1-(9–36) NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans

Vahl et al., 2003

View HTML
Document ID
6764294270490293102
Author
Vahl T
Paty B
Fuller B
Prigeon R
D’Alessio D
Publication year
Publication venue
The Journal of Clinical Endocrinology & Metabolism

External Links

Snippet

Glucagon-like peptide 1 (GLP-1) is an insulin secretagogue synthesized in the intestine and released in response to meal ingestion. It is secreted primarily in two forms, GLP-1-(7–37) and GLP-1-(7–36) NH2, both of which bind to a specific GLP-1 receptor (GLP-1r) on the …
Continue reading at academic.oup.com (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients

Similar Documents

Publication Publication Date Title
Vahl et al. Effects of GLP-1-(7–36) NH2, GLP-1-(7–37), and GLP-1-(9–36) NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans
Egan et al. Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state
Toft-Nielsen et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Salehi et al. Regulation of islet hormone release and gastric emptying by endogenous glucagon-like peptide 1 after glucose ingestion
Filipsson et al. Pituitary adenylate cyclase-activating polypeptide stimulates insulin and glucagon secretion in humans
Vilsbøll et al. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects
Deacon et al. Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs
Mentis et al. GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes
Toft-Nielsen et al. Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes
Meier et al. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia
Ahren et al. Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus
Hartmann et al. In vivo and in vitro degradation of glucagon-like peptide-2 in humans
Vilsbøll et al. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus
Rask et al. Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men
Henry et al. Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers
Vilsbøll et al. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide—regardless of etiology and phenotype
Nauck et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers
Vahl et al. Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats
Egan et al. The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes
Carr et al. Secretion and dipeptidyl peptidase-4-mediated metabolism of incretin hormones after a mixed meal or glucose ingestion in obese compared to lean, nondiabetic men
Mannucci et al. Glucagon‐like peptide (GLP)‐1 and leptin concentrations in obese patients with Type 2 diabetes mellitus
Ahrén et al. Characterization of GLP-1 effects on β-cell function after meal ingestion in humans
Bramnert et al. Growth hormone replacement therapy induces insulin resistance by activating the glucose-fatty acid cycle
Degn et al. One week’s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and α-and β-cell function and reduces endogenous glucose release in patients with type 2 diabetes
De Groot Non-thyroidal illness syndrome is a manifestation of hypothalamic-pituitary dysfunction, and in view of current evidence, should be treated with appropriate replacement therapies